Ennature Biopharma

Noida, India Founded: 2009 • Age: 17 yrs Listed
Manufactures and supplies pure nicotine, pharmaceutical actives, and nutraceutical ingredients globally.
Request Access
Report Incorrect Data
Page last updated

About Ennature Biopharma

Ennature Biopharma is a publicly listed company based in Noida (India) founded in 2009. It manufactures and supplies pure nicotine, pharmaceutical actives, and nutraceutical ingredients globally. It operates on a B2B model. The company has 1,347 employees. Its Indian entity India Glycols Limited reported revenue of ₹4,263 Cr. Ennature Biopharma offers products and services including Pure Nicotine, Active Pharmaceutical Ingredients, Branded Nutraceutical Ingredients, and Standardized Botanical Extracts. Its focus areas include Biotechnology, Nutraceuticals, Plant Extracts and Standardized Botanicals. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Ennature Biopharma, a division of India Glycols Limited, produces high-quality ingredients for pharmaceuticals and nutraceuticals using advanced green extraction technologies like CO2 systems. Based in Noida, India, they focus on pure nicotine, botanical extracts, and active pharmaceuticals, adhering to global standards. The company serves international nutraceutical and pharmaceutical firms, emphasizing sustainability, quality, and innovation in their processes.

  • Headquarters Noida, India
  • Employees 1,347
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website ennaturebiopharma.com
  • Social LinkedIn
  • Legal Name India Glycols Limited
  • Date of Incorporation 19 Nov, 1983
  • Jurisdiction Udham Singh Nagar, Uttarakhand, India
Operational Areas
Healthcare → Nutraceutical & Food-as-Medicine Platforms
Key Metrics
  • Market Cap
    ₹2,223 Cr

    INDIAGLYCO · NSE

  • Share Price
    ₹332.10

    +0.12% today

  • Revenue
    ₹4,211 Cr

    FY 2025-26 · +11.8% YoY

  • EBITDA
    ₹648 Cr

    Margin 15.4%

  • Net Profit
    ₹292 Cr

    FY 2025-26 · +27.2% YoY

  • P/E (TTM)
    7.0x

    P/B 0.8x

  • ROE
    11.3%

    ROCE 12.2%

  • Debt / Equity
    0.69

    Interest cover 33.9x

  • Employee Count
    1,347

Products & Services of Ennature Biopharma

Ennature Biopharma offers a comprehensive portfolio of products and services, including Pure Nicotine, Active Pharmaceutical Ingredients, Branded Nutraceutical Ingredients, and Standardized Botanical Extracts.

Pure Nicotine
Chemical Products

Supplies nicotine for e-liquids and pharmaceuticals applications.

Active Pharmaceutical Ingredients
Pharmaceuticals

Produces actives meeting global regulatory standards.

Branded Nutraceutical Ingredients
Nutraceuticals

Offers phytochemical solutions for health supplements.

Standardized Botanical Extracts
Natural Extracts

Provides pure extracts for nutraceutical use.

Board of directors of India Glycols Limited (Ennature Biopharma)

India Glycols Limited is the primary company behind Ennature Biopharma. The board of India Glycols Limited currently have 8 directors; the longest-serving is Uma Shankar Bhartia, appointed in 1996. 17 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Uma Shankar Bhartia
DIN 00063091
Managing Director29 Nov 199629 yrs 11 moIndia Glycols Limited
Jayshree Bhartia
DIN 00063018
Director28 May 199927 yrs 5 moIndia Glycols Limited
Shukla Wassan
DIN 02770898
Director01 Apr 20206 yrs 7 moIndia Glycols Limited
Pragya Bhartia Barwale
DIN 02109262
Director24 Jun 20206 yrs 4 moIndia Glycols Limited
Alok Singhal
DIN 10359043
Whole-time director01 Dec 20232 yrs 11 moIndia Glycols Limited
Ravi Kumar
DIN 02362615
Director02 Feb 20242 yrs 8 moIndia Glycols Limited
Samrat Banerjee
DIN 06706345
Director01 Oct 20242 yrs 1 moIndia Glycols Limited
Sushil Dutt Salwan
DIN 10776621
Director01 Oct 20242 yrs 1 moIndia Glycols Limited

People of Ennature Biopharma

1 people are tracked at Ennature Biopharma (1 in leadership); the tracked headcount is 1,347.

NameRoleGroup
Pragya Bhartia
Executive DirectorLeadership
Premium access

Complete people profiles for Ennature Biopharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ennature Biopharma

Ennature Biopharma is a publicly listed company on the NSE with ticker symbol INDIAGLYCO in India, operating in the Alcoholic Beverages sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: INDIAGLYCO
  • Listed entityIndia Glycols Limited
  • Exchange sectorAlcoholic Beverages

Financials of Ennature Biopharma

Exchange-reported figures of India Glycols Limited, the listed company behind Ennature Biopharma (NSE: INDIAGLYCO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,211 Cr
+11.8% YoY
EBITDA
₹648 Cr
+26.9% YoY
Profit After Tax
₹292 Cr
+27.2% YoY
Net Worth
₹2,933 Cr
+30.0% YoY
Total Assets
₹4,694 Cr
+11.8% YoY
Total Debt
₹1,691 Cr
-10.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,2113,7683,2942,6512,8682,3172,735
Revenue growth+11.8%+14.4%+24.3%-7.6%+23.8%-15.3%-
EBITDA648511402296(173)268278
EBITDA margin+15.4%+13.6%+12.2%+11.2%-6.0%+11.6%+10.2%
Profit before tax377292223165379143153
Net profit292230179108164153130
Net profit margin+6.9%+6.1%+5.4%+4.1%+5.7%+6.6%+4.8%
EPS (₹)43.6874.5855.8740.40109.7742.5137.03
Balance sheet
Total assets4,6944,1973,4473,1823,0502,6502,361
Net worth2,9332,2562,0511,9011,7971,1691,034
Total debt1,6911,8921,3481,1121,0421,137999
Cash & bank49.8377.4413811310297.5491.71
Net working capital174280173328365215189
Cash flow
Cash from operations769362439326116137343
Cash from investing(767)(736)(503)(330)76.45(148)(151)
Cash from financing22.5435489.91(0.51)(189)10.75(216)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1309761,1021,0921,040863975961
Revenue growth (YoY)+8.6%+13.1%+13.0%+13.6%+7.4%---
Other income20.9813.604.0013.7320.0212.9719.3015.16
EBITDA170166175158150146124116
EBITDA margin+15.0%+17.1%+15.8%+14.4%+14.4%+16.9%+12.7%+12.0%
Depreciation42.4841.2341.2238.4834.4532.5927.4727.57
Interest25.1826.4146.8149.2844.6844.5344.0739.91
Profit before tax12311290.6183.6190.5381.7971.4263.46
Tax26.0525.5823.0418.5517.2817.7714.6113.75
Net profit96.8386.8867.5765.0673.2564.0256.8149.71
EPS (₹)14.4513.6410.7910.5123.6620.6818.3516.06
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,2113,7673,2912,6502,8632,2802,714
Revenue growth+11.8%+14.5%+24.2%-7.4%+25.6%-16.0%-
EBITDA646507398252232258278
EBITDA margin+15.3%+13.5%+12.1%+9.5%+8.1%+11.3%+10.2%
Profit before tax367242202123352143166
Net profit28217914911212384.34128
Net profit margin+6.7%+4.8%+4.5%+4.2%+4.3%+3.7%+4.7%
EPS (₹)42.1258.2649.0031.8992.1827.2341.43
Balance sheet
Total assets4,2993,8123,1122,8682,7122,6532,413
Net worth2,5371,8711,7161,5881,5121,2451,158
Total debt1,6911,8921,3481,1129691,064928
Cash & bank49.0377.1113811310197.1583.88
Net working capital167276173332424286266
Cash flow
Cash from operations769362438326114142344
Cash from investing(767)(736)(503)(330)76.80(157)(156)
Cash from financing22.5435489.93(0.42)(188)15.90(212)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1299781,1021,0911,040863975961
Revenue growth (YoY)+8.5%+13.4%+13.1%+13.5%+7.4%---
Other income0.3839.200.742.171.401.595.824.34
Total expenses959814927932893719851845
EBITDA170164176158148144124116
EBITDA margin+15.1%+16.8%+15.9%+14.5%+14.2%+16.7%+12.7%+12.1%
Depreciation42.4841.2341.2238.4834.4532.5927.4627.58
Interest25.1826.4146.8149.2844.6844.5344.0739.91
Profit before tax10313688.3072.4970.1368.1258.4553.20
Tax26.0525.5023.0418.5517.2817.7714.6113.75

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1309761,1021,0921,040863975961
Revenue growth (YoY)+8.6%+13.1%+13.0%+13.6%+7.4%---
Other income20.9813.604.0013.7320.0212.9719.3015.16
EBITDA170166175158150146124116
EBITDA margin+15.0%+17.1%+15.8%+14.4%+14.4%+16.9%+12.7%+12.0%
Depreciation42.4841.2341.2238.4834.4532.5927.4727.57
Interest25.1826.4146.8149.2844.6844.5344.0739.91
Profit before tax12311290.6183.6190.5381.7971.4263.46
Tax26.0525.5823.0418.5517.2817.7714.6113.75
Net profit96.8386.8867.5765.0673.2564.0256.8149.71
EPS (₹)14.4513.6410.7910.5123.6620.6818.3516.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,2113,7683,2942,6512,8682,3172,735
Revenue growth+11.8%+14.4%+24.3%-7.6%+23.8%-15.3%-
Other income51.3560.9542.3963.4070238.3948.57
Total expenses3,5633,2572,8922,3553,0412,0492,457
Employee cost13312310388.8089.1683.3393.28
EBITDA648511402296(173)268278
EBITDA margin+15.4%+13.6%+12.2%+11.2%-6.0%+11.6%+10.2%
Depreciation15511510193.9680.2980.1277.53
Interest16716412199.9669.6683.3896.90
Profit before tax377292223165379143153
Tax84.4561.4050.3223.9639.4311.2837.87
Net profit292230179108164153130
Net profit margin+6.9%+6.1%+5.4%+4.1%+5.7%+6.6%+4.8%
EPS (₹)43.6874.5855.8740.40109.7742.5137.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital33.5130.9630.9630.9635.8630.9630.96
Reserves & surplus2,8992,2252,0201,8701,7611,1381,003
Shareholders' funds (net worth)2,9332,2562,0511,9011,7971,1691,034
Minority interest0.000.000.000.00(19.48)0.000.00
Secured loans1,5291,7331,2461,008884986862
Unsecured loans162159102104158150137
Total debt1,6911,8921,3481,1121,0421,137999
Total liabilities4,6944,1973,4473,1823,0502,6502,361
Assets
Gross block5,3624,4823,7463,1582,7272,5812,594
Net block4,5543,8293,2052,7172,3182,1932,228
Capital work in progress36.7098.3983.55125243126172
Investments38938133531833627.0726.35
Inventories8911,1711,106754693610682
Sundry debtors351365384430399362569
Cash & bank balances49.8377.4413811310297.5491.71
Loans & advances206203316349414259252
Total current assets1,4981,8161,9451,6461,6071,3281,595
Total current liabilities1,3241,5371,7721,3181,2421,1121,406
Net working capital174280173328365215189
Total assets4,6944,1973,4473,1823,0502,6502,361
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.8426.961.977.053.393.6526.96
Net cash from operating activities769362439326116137343
Net cash from investing activities(767)(736)(503)(330)76.45(148)(151)
Net cash from financing activities22.5435489.91(0.51)(189)10.75(216)
Net change in cash25.03(20.12)24.98(5.07)3.66(0.26)(23.32)
Closing cash49.8377.4413811310297.5491.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.8%+14.4%+24.3%-7.6%+23.8%-15.3%-
EBITDA growth+26.9%+27.0%+36.2%+270.8%-164.6%-3.7%-
PBT growth+29.0%+30.9%+35.3%-56.5%+165.4%-6.3%-28.4%
Net income growth+27.2%+28.1%+66.6%-34.5%+7.3%+17.6%-
Revenue CAGR (3Y)+16.7%+9.5%+12.4%-1.0%-5.1%-8.6%+3.1%
EBITDA CAGR (3Y)+29.9%-+14.5%+2.0%--6.0%+5.6%
Profitability & leverage
Net income margin+7.0%+6.1%+5.3%+5.3%+11.9%+5.7%+4.2%
Return on capital employed+12.3%+12.0%+10.4%+7.8%+8.1%+9.0%+11.6%
Return on net worth+11.3%+10.7%+8.8%+6.7%+11.1%+12.0%+13.0%
Debt / equity0.690.750.620.580.730.971.00
Long-term debt / equity0.410.430.330.300.350.430.41
Interest cover33.9141.5340.0149.59-27.5044.3848.24
Efficiency & per share
Fixed asset turnover2.002.202.292.262.492.102.07
Inventory turnover9.537.948.529.1810.138.407.85
Debtors turnover27.4324.1319.4516.0217.3611.6711.71
EPS (₹)43.6874.5855.8740.40109.7742.5137.03
Dividend per share (₹)7.5010.008.007.507.506.006.00
Book value per share (₹)437.55728.61662.44614.12578.75377.41333.92
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,1299781,1021,0911,040863975961
Revenue growth (YoY)+8.5%+13.4%+13.1%+13.5%+7.4%---
Other income0.3839.200.742.171.401.595.824.34
Total expenses959814927932893719851845
EBITDA170164176158148144124116
EBITDA margin+15.1%+16.8%+15.9%+14.5%+14.2%+16.7%+12.7%+12.1%
Depreciation42.4841.2341.2238.4834.4532.5927.4627.58
Interest25.1826.4146.8149.2844.6844.5344.0739.91
Profit before tax10313688.3072.4970.1368.1258.4553.20
Tax26.0525.5023.0418.5517.2817.7714.6113.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,2113,7673,2912,6502,8632,2802,714
Revenue growth+11.8%+14.5%+24.2%-7.4%+25.6%-16.0%-
Other income43.5114.5525.7355.7225834.4951.99
Total expenses3,5653,2602,8932,3982,6322,0222,436
Employee cost13112110287.1387.5981.6991.39
EBITDA646507398252232258278
EBITDA margin+15.3%+13.5%+12.1%+9.5%+8.1%+11.3%+10.2%
Depreciation15511510189.6575.9875.8173.20
Interest16716412195.1962.1773.4590.24
Profit before tax367242202123352143166
Tax84.3761.4050.3223.9666.2658.4337.87
Net profit28217914911212384.34128
Net profit margin+6.7%+4.8%+4.5%+4.2%+4.3%+3.7%+4.7%
EPS (₹)42.1258.2649.0031.8992.1827.2341.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital33.5130.9630.9630.9630.9630.9630.96
Reserves & surplus2,5041,8401,6851,5571,4811,2141,127
Shareholders' funds (net worth)2,5371,8711,7161,5881,5121,2451,158
Secured loans1,5291,7331,1961,008884986862
Unsecured loans16215915210484.7477.5366.14
Total debt1,6911,8921,3481,1129691,064928
Total liabilities4,2993,8123,1122,8682,7122,6532,413
Assets
Gross block5,3664,4863,7503,1622,6112,4652,477
Net block4,5543,8293,2052,7172,2322,1022,134
Capital work in progress36.7098.3983.55125237119163
Investments0.040.040.031.5728.6228.6128.59
Inventories8881,1691,104753689606679
Sundry debtors353366389436402365574
Cash & bank balances49.0377.1113811310197.1583.88
Loans & advances200200313346451312301
Total current assets1,4901,8121,9441,6481,6441,3791,638
Total current liabilities1,3221,5361,7711,3171,2201,0941,372
Net working capital167276173332424286266
Total assets4,2993,8123,1122,8682,7122,6532,413
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.5126.751.816.643.002.7626.53
Net cash from operating activities769362438326114142344
Net cash from investing activities(767)(736)(503)(330)76.80(157)(156)
Net cash from financing activities22.5435489.93(0.42)(188)15.90(212)
Net change in cash24.55(20.24)24.94(4.83)3.640.24(23.77)
Closing cash49.0377.1113811310197.1583.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.8%+14.5%+24.2%-7.4%+25.6%-16.0%-
EBITDA growth+27.4%+27.4%+58.0%+8.7%-10.0%-7.2%-
PBT growth+51.7%+19.7%+64.7%-65.1%+146.4%-14.1%-27.4%
Net income growth+57.3%+20.5%+33.2%-8.9%+45.3%-34.2%-
Revenue CAGR (3Y)+16.7%+9.6%+13.0%-0.8%-5.2%-9.0%+3.1%
EBITDA CAGR (3Y)+36.9%+29.8%+15.6%-3.2%-18.0%-7.5%+5.5%
Profitability & leverage
Net income margin+6.7%+4.8%+4.6%+3.7%+10.0%+3.7%+4.7%
Return on capital employed+13.2%+11.7%+10.8%+8.4%+7.6%+7.7%+10.6%
Return on net worth+12.8%+10.1%+9.2%+7.2%+8.9%+7.0%+11.5%
Debt / equity0.810.900.740.670.740.830.83
Long-term debt / equity0.480.500.350.300.330.340.33
Interest cover34.0941.9740.6358.7039.9440.4344.15
Efficiency & per share
Fixed asset turnover1.992.192.292.302.602.182.16
Inventory turnover9.557.958.539.2110.198.397.86
Debtors turnover27.3423.9319.1815.8417.2011.4811.50
EPS (₹)42.1258.2649.0031.8992.1827.2341.43
Dividend per share (₹)7.5010.008.007.507.506.006.00
Book value per share (₹)378.57604.31554.33512.77488.27402.12373.94

Similar companies to Ennature Biopharma

Ennature Biopharma has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Ennature Biopharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Nutraceutical & Food-as-Medicine Platforms

3 companies that operate in the same segment as Ennature Biopharma (Nutraceutical & Food-as-Medicine Platforms) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Kapiva
Ayurvedic healthcare and nutritional products are provided by Kapiva.
2016Bengaluru, Karnataka, IndiaUSD 77.85 MUSD 27.35 M362
OmniActive
Nutritional supplements for multiple health ailments are developed.
2005Mumbai, Maharashtra, IndiaUSD 1.55 M
OZiva
Nutritional food and health supplements are provided by OZiva.
2010Mumbai, Maharashtra, IndiaUSD 17.32 MUSD 23.98 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ennature Biopharma

Nifty Sugar & Alcohol Index: The debate is settling, the business is moving. Time to look at a larger set? 9 sugar-ethanol ecosystem stocks for the watchlist - The Economic Times
Economic Times • 28 days ago
India Glycols Ltd leads gainers in 'A' group | Capital Market News - Business Standard
Business Standard • 1 month ago
Oracle Financial Services Software Ltd leads losers in 'A' group | Capital Market News - Business Standard
Business Standard • 1 month ago
Avalon Technologies Ltd leads gainers in 'A' group | Capital Market News - Business Standard
Business Standard • 1 month ago
India Glycols shares: Why this multibagger stock is showing 80% crash in some trading apps today - BusinessToday
Business Today • 2 months ago
IFCI Ltd leads gainers in 'A' group | Capital Market News - Business Standard
Business Standard • 2 months ago
India Glycols shares jump 5% after adjusting for demerger into three separate entities - CNBC TV18
CNBCTV18 • 2 months ago
Broker’s Call: India Glycols (Buy) - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Multibagger stock India Glycols drops 3% after 4 days of gains; should you buy the stock as it readies for a demerger?
Mint • 2 months ago
India Glycols consolidated net profit rises 32.19% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Premium access

Complete news archive for Ennature Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ennature Biopharma

Ennature Biopharma was founded in 2009.

Ennature Biopharma is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.

Ennature Biopharma has 1,347 employees.

The primary company behind Ennature Biopharma, India Glycols Limited, reported revenue of ₹4,263 Cr for FY 2026, up 12% year on year.

Ennature Biopharma, a division of India Glycols Limited, produces high-quality ingredients for pharmaceuticals and nutraceuticals using advanced green extraction technologies like CO2 systems. Based in Noida, India, they focus on pure nicotine, botanical extracts, and active pharmaceuticals, adhering to global standards. The company serves international nutraceutical and pharmaceutical firms, emphasizing sustainability, quality, and innovation in their processes.

Ennature Biopharma's top competitors include Laurus Labs, Symbiotec and SeQuent.

Ennature Biopharma offers Pure Nicotine, Active Pharmaceutical Ingredients, Branded Nutraceutical Ingredients, and Standardized Botanical Extracts.

Yes, Ennature Biopharma is publicly traded on NSE under the ticker symbol INDIAGLYCO.

Ennature Biopharma operates through India Glycols Limited.

The legal entities of Ennature Biopharma currently have 11 directors, including Uma Shankar Bhartia, Pragya Bhartia Barwale, Rupark Chandi Sarswat and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available